FDA approves Cobenfy: A breakthrough Schizophrenia treatment after decades
Friday, 27 September 2024 ()
The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This approval introduces a novel pharmacological approach after more than 30 years. The drug will be available by late October at $1,850 per month before insurance and rebates. Clinical trials have shown significant improvement in symptoms compared to a placebo.
|
||||
|
|
||||
You Might Like |
||||
